It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microbial Ni2+ homeostasis underpins the virulence of several clinical pathogens. Ni2+ is an essential cofactor in urease and [NiFe]-hydrogenases involved in colonization and persistence. Many microbes produce metallophores to sequester metals necessary for their metabolism and starve competing neighboring organisms. The fungal metallophore aspergillomarasmine A (AMA) shows narrow specificity for Zn2+, Ni2+, and Co2+. Here, we show that this specificity allows AMA to block the uptake of Ni2+ and attenuate bacterial Ni-dependent enzymes, offering a potential strategy for reducing virulence. Bacterial exposure to AMA perturbs H2 metabolism, ureolysis, struvite crystallization, and biofilm formation and shows efficacy in a Galleria mellonella animal infection model. The inhibition of Ni-dependent enzymes was aided by Zn2+, which complexes with AMA and competes with the native nickelophore for the uptake of Ni2+. Biochemical analyses demonstrated high-affinity binding of AMA-metal complexes to NikA, the periplasmic substrate-binding protein of the Ni2+ uptake system. Structural examination of NikA in complex with Ni-AMA revealed that the coordination geometry of Ni-AMA mimics the native ligand, Ni-(l-His)2, providing a structural basis for binding AMA-metal complexes. Structure-activity relationship studies of AMA identified regions of the molecule that improve NikA affinity and offer potential routes for further developing this compound as an anti-virulence agent.
Aspergillomarasmine A (AMA) chelates metal ions such as Zn2+ and Ni2+, which are essential for the activity of enzymes that are important for virulence of several pathogens. Here, Sychantha et al. show that AMA inhibits bacterial Ni2+ uptake and Ni-dependent enzymes, and reduces bacterial virulence in an animal infection model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 McMaster University, David Braley Centre for Antibiotic Discovery, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227); McMaster University, M.G. DeGroote Institute for Infectious Disease Research, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227); McMaster University, Department of Biochemistry and Biomedical Sciences, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227); University of Waterloo, Department of Chemistry, Waterloo, Canada (GRID:grid.46078.3d) (ISNI:0000 0000 8644 1405)
2 McMaster University, David Braley Centre for Antibiotic Discovery, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227); McMaster University, M.G. DeGroote Institute for Infectious Disease Research, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227); McMaster University, Department of Biochemistry and Biomedical Sciences, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227)
3 University of Manitoba, Department of Microbiology, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)